ClinicalTrials.gg
Active, not recruitingNCT05907954Updated Mar 16, 2026

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

A Phase 2 interventional study of Darovasertib in Uveal Melanoma, sponsored by IDEAYA Biosciences. Active, not recruiting at 18 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by IDEAYA Biosciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 190 studies in Uveal Melanoma with a site in United States — 25 open to participants now, 50 under way, 7 of them phase 3. Uveal Melanoma · United States.

Planned enrollment
17th of 162
160 · median 36
Started
2023
with 6 others
Phase 2
79 of 190
7 open now
Primary completion
2027-04
later than 20 of 49 live
Registered
166th of 190
by date
Lead sponsor
5 of 190
IDEAYA Biosciences

Among the 190 studies in Uveal Melanoma with a site in United States, this one is the 17th largest by planned enrollment of the 162 interventional ones that give a count, is one of 7 that started in 2023, is one of 79 in phase 2, reaches primary completion later than 20 of the 49 other live ones, and was the 166th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

25 of the 190 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Uveal Melanoma studies recruiting now, 35 (83%) set no upper age limit and 4 (10%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

Read the detailed description

Phase 2 multi-center open-label IDE196 study in patients with primary uveal melanoma (UM) requiring either enucleation or plaque brachytherapy. Patients will be treated in neoadjuvant setting up to 12 months (or maximum benefit) followed by primary local therapy. An additional 6 months of adjuvant treatment may be given to some patients. All patients will have long term follow-up (up to 3 years) to assess visual outcome, disease recurrence, and development of metastatic disease.

03

Conditions studied

  • Uveal Melanoma

Browse trials for

Keywords

  • Uveal Melanoma
  • Plaque brachytherapy
  • Enucleation
  • Neoadjuvant
  • Adjuvant
  • Protein Kinase C
  • Ophthalmology
  • Ocular Oncology
  • Darovasertib
  • IDE196
  • Ocular melanoma
  • Choroid melanoma
  • Plaque
  • Brachytherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary localized uveal melanoma requiring either enucleation or plaque brachytherapy
  • Cohort 3 (patients with small UM tumors) - clinically diagnosed uveal (not iris) melanoma that is \< 4 mm in thickness requiring treatment
  • Able to dose orally
  • Performance status of 0-1
  • No other significant underlying ocular disease
  • Adequate organ function
  • Not pregnant/nursing or planning to become pregnant. Willing to use

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with a Protein Kinase C (PKC) inhibitor
  • Concurrent malignant disease
  • Active infection or Hep B/C
  • Malabsorption disorder
  • Unable to discontinue prohibited medication
  • Impaired cardiac function or cardiac disease
  • Any other condition which may interfere with study interpretation or results
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    darovasertib

    IDE196 (darovasertib) oral open label

    Drug: Darovasertib

Interventions

  • Oral, potent, selective inhibitor of Protein Kinase C

    Also known as: IDE196, LXS196

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) and significant laboratory abnormalities

    Treatment emergent adverse events will be summarized by all AEs, all Grade 3-4-5 AEs, all treatment related AEs, all AEs leading to study drug modifications or discontinuations, all SAEs. Lab results will be summarized by change from baseline values, frequency of newly occurring on-treatment Grade 3 or 4 events; worst on-treatment value compared to baseline.

    Time frame: from first dose to 28 days after last dose of therapy, approximately 18 months

  2. Cohort 1 (enucleation): Number of patients converted from requiring enucleation to radiation

    Rate of eye salvage as determined by the ocular oncologist based on tumor response to neoadjuvant therapy

    Time frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months

  3. Cohort 2 (plaque brachytherapy): Estimated change in modeled radiation dose

    Change in modeled radiation dose at critical eye structures before and after neoadjuvant therapy

    Time frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months

  4. Cohort 3 (patients with small UM tumors): Number of patients with clinical benefit per protocol-defined UM response criteria

    Proportion of patients with clinical benefit rate (CBR) defined as complete response (CR) + partial response (PR) + stable disease (SD) for ≥ 12 weeks per UM response criteria

    Time frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months

Secondary outcomes

  1. Evaluate tumor response to neoadjuvant IDE196

    Measurement of tumor diameter and thickness before and after neoadjuvant therapy with IDE196, specifically as measured by ocular ultrasound, evaluating largest basal diameter and apical thickness of the uveal melanoma (measured in millimeters)

    Time frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months

  2. Assessment of visual acuity loss

    Best corrected visual acuity loss over time

    Time frame: from time of primary local therapy to one year after surgery, approximately 12 months

  3. Rate of local disease recurrence

    Evaluate uveal melanoma progression or recurrence

    Time frame: from date of primary local therapy to end of follow-up, approximately 36 months

  4. Cohort 3 (patients with small UM tumors): Effect of neoadjuvant IDE196 therapy on the natural history of small UM tumors

    Time from first dose of neoadjuvant to primary local therapy

    Time frame: from first dose of neoadjuvant to primary local therapy, approximately 12 months

  5. Cohort 3 (patients with small UM tumors): Efficacy of neoadjuvant IDE196 therapy on small UM tumors

    Tumor response (complete response and partial response) as measured by protocol-defined UM response criteria

    Time frame: from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months

Other outcomes

  1. Rate of metastatic disease

    Evaluate occurrence of metastatic uveal melanoma

    Time frame: from date of primary local therapy to end of follow-up, approximately 36 months

  2. Overall survival

    Evaluate patient survival status

    Time frame: from date of first dose to end of follow-up, approximately 54 months

07

Study locations

18 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Apr 2027, 45 months after the start.

Of 46 phase 2 interventional studies under Uveal Melanoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's planned 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jun 18, 2023
StartActual
Jul 3, 2023
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2030
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05907954
Lead sponsor
IDEAYA Biosciences
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jul 3, 2023
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Mar 16, 2026

Study contacts

Jasgit Sachdev, MD
study director · IDEAYA Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darovasertib

Start the discussion